These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. Hou JZ; Ye JC; Pu JJ; Liu H; Ding W; Zheng H; Liu D J Hematol Oncol; 2021 Apr; 14(1):66. PubMed ID: 33879198 [TBL] [Abstract][Full Text] [Related]
7. Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. Zhu X; Ma Y; Liu D J Hematol Oncol; 2010 Apr; 3():17. PubMed ID: 20416083 [TBL] [Abstract][Full Text] [Related]
8. Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting. Tan J; Tan H; Li Y Exp Hematol Oncol; 2023 Jul; 12(1):62. PubMed ID: 37468979 [TBL] [Abstract][Full Text] [Related]
9. Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting. Zhang W; Li S; Long J; Xie S; Wang M; Liu H; Xu Z Exp Hematol Oncol; 2024 Apr; 13(1):43. PubMed ID: 38637863 [TBL] [Abstract][Full Text] [Related]
10. Report on the 56th ASH Annual Meeting, San Francisco, 4-9 December 2014. Agazzi A Ecancermedicalscience; 2015; 9():514. PubMed ID: 25729427 [TBL] [Abstract][Full Text] [Related]
11. Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Tefferi A; Abdel-Wahab O; Cervantes F; Crispino JD; Finazzi G; Girodon F; Gisslinger H; Gotlib J; Kiladjian JJ; Levine RL; Licht JD; Mullally A; Odenike O; Pardanani A; Silver RT; Solary E; Mughal T Blood Cancer J; 2011 Mar; 1(3):e7. PubMed ID: 23471017 [TBL] [Abstract][Full Text] [Related]
12. Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting. Gong X; Zhang Y; He X; Moloudizargari M; Yu T; Wang L; Liu W; Jin L; Xu H; Xu Y; Tao Z; Qian W Exp Hematol Oncol; 2023 Jun; 12(1):57. PubMed ID: 37391809 [TBL] [Abstract][Full Text] [Related]
13. Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting. Zhong G; Kong R; Feng S; Wang C; Hao Q; Xie W; Zhou X J Hematol Oncol; 2024 Mar; 17(1):14. PubMed ID: 38520028 [TBL] [Abstract][Full Text] [Related]
14. Post-ASH Second Annual Meeting. 21 December 1999, Grimbergen, Belgium. Van Bockstaele D IDrugs; 2000 Mar; 3(3):268-72. PubMed ID: 16103930 [No Abstract] [Full Text] [Related]
15. 63rd ASH Annual Meeting and Exposition. Lai C Lancet Oncol; 2022 Jan; 23(1):e19-e20. PubMed ID: 34922647 [No Abstract] [Full Text] [Related]